已收录 270995 条政策
 政策提纲
  • 暂无提纲
Potential Effects of Silymarin and Its Flavonolignan Components in Patients with ?-Thalassemia Major: A Comprehensive Review in 2015
[摘要] Major ?-thalassemia (?-TM) is one of the most common inherited hemolytic types of anemia which is caused as a result of absent or reduced synthesis of ?-globin chains of hemoglobin. This defect results in red blood cells lysis and chronic anemia that can be treated by multiple blood transfusions and iron chelation therapy. Without iron chelation therapy, iron overload will cause lots of complications in patients. Antioxidant components play an important role in the treatment of the disease. Silymarin is an antioxidant flavonoid isolated from Silybum marianum plant. In the present study, we reviewed clinical and experimental studies investigating the use of silymarin prior to September 1, 2015, using PubMed, ISI Web of Knowledge, Science Direct, Scopus, Ovid, and Cochrane Library databases and we evaluated the potential effects of silymarin on controlling the complications induced by iron overload in patients with ?-TM. Based on the results of the present study, we can conclude that silymarin may be useful as an adjuvant for improving multiple organ dysfunctions.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 药学
[关键词]  [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文